Vineet Laboratories growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
−20.8%−50.2%−29.1%
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
+152.1%−326.1%−6.0%
+132.3%−501.3%−11.5%
+107.9%−2,066.0%−18.0%
+104.6%−2,073.0%−18.4%
+32.0%−19.1%+0.9%
+211.3%−57.8%+3.1%
−206.6%+200.6%−18.8%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

VINEETLAB₹37.76

Vineet Laboratories Limited

· Pharma & Health
₹ CrorePeersBIOFILCHEMMANGALAMLASAKREBSBIOALPABALPHARMAORTINGLOBENATCAPSUQMcap ₹72.5 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue Growth—-29.1-50.2-20.8—
EBITDA Growth—-6.0-326.1+152.1—
EBIT Growth—-11.5-501.3+132.3—
Net Income Growth—-18.0-2,066.0+107.9—
EPS Growth—-18.4-2,073.0+104.6—
Total Assets Growth—+0.9-19.1+32.0—
Total Equity Growth—+3.1-57.8+211.3—
Cash from Operations Growth—-18.8+200.6-206.6—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.